

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Xikang Cloud Hospital Holdings Inc.

### 熙康雲醫院控股有限公司

(Formerly known as Neusoft Xikang Holdings Inc. 東軟熙康控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9686)

## INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

### FINANCIAL HIGHLIGHTS

	For the six months ended June 30,		
	2025	2024	Change
	RMB'000	RMB'000	
Revenue	178,605	179,214	(609)
Gross profit	39,313	42,556	(3,243)
Gross margin	22.0%	23.7%	(1.7%)
Loss for the period	(49,975)	(60,484)	10,509
Add: Share-based compensation expenses	11,571	9,182	2,389
Adjusted net loss for the period (non-HKFRS measure)	(38,404)	(51,302)	12,898

The board (the “**Board**”) of directors (the “**Director(s)**”) of Xikang Cloud Hospital Holdings Inc. (the “**Company**”) is pleased to announce the unaudited interim results of the Company, its subsidiaries and the consolidated affiliated entities controlled under the contractual arrangements (together, the “**Group**”) for the six months ended June 30, 2025 (the “**Reporting Period**”), as well as the comparative figures for the same period in 2024. The above interim results have been prepared in accordance with Hong Kong Accounting Standards, and have been reviewed by the audit committee of the Company (the “**Audit Committee**”) and the independent auditor of the Company.

During the Reporting Period, the Company focused on its core business and continued optimization of business structure, and we recorded a total revenue of RMB178.6 million (for the six months ended June 30, 2024: RMB179.2 million), representing a year-on-year decrease of 0.3% as compared to the same period of 2024. During the Reporting Period, we carried on optimizing resource allocation and reinforced the monitoring of our input and output, which resulted in a decrease in our net loss by 17.4% to RMB50.0 million (for the six months ended June 30, 2024: RMB60.5 million).

## **MANAGEMENT DISCUSSION AND ANALYSIS**

### **I. BUSINESS REVIEW**

We have been adhering to building a “City-Specific Cloud Hospital Platform” that takes the city as the gateway and closely and deeply correlates with the regional medical and health system. With strong support from local governments, we efficiently, scalably, and cost-effectively aggregate urban medical resources, empowering doctors and nurses to deliver more professional and accessible medical and nursing services to patients across cities. Our in-depth understanding of government services and regulatory frameworks, coupled with our extensive partnership network, forms a unique and inimitable competitive edge.

Leveraging advanced AI models and big data analytics, we continuously optimize the precision matching between urban healthcare resources and medical demands, enhancing equitable resource accessibility and fostering a more efficient regional digital healthcare ecosystem. We continue to extend professional medical and nursing services to every household within a city through technological innovation and service upgrades, turning the bed at patients’ households into the seamless extension of beds at hospitals, ensuring the medical services and nursing services in home settings are as safe, reliable and effective as those in hospitals, and realizing a seamless transition of medical and nursing care.

#### **The Uniqueness of “City-Specific Cloud Hospital Platform” Business Model**

Anchored by strategic government collaboration to ensure platform credibility: We leverage local governments as policy-makers, regulators and major payers of China’s health industry as the strategic focus. Our “City-Specific Cloud Hospital Platform” model is closely connected and deeply linked with the regional medical and health service system, thus accelerating the cooperation with medical institutions with local governments as the core breakthrough, to ensure the credibility of our platform.

Batch City-Level Deployment for Standardized Replication: With the “top-down” urban expansion strategy, we efficiently connect all medical resources within the region, leading to the fast promotion of medical institutions, doctors and nurses joining our platform intensively. This enables rapid establishment of localized cloud hospital platforms, leveraging our full-scenario service ecosystem (Medical + Nursing + Health Management) and validated operational protocols to drive scalable replication and market expansion.

AI-Driven Innovation for a Smarter Healthcare New Ecosystem: Powered by our multimodal AI technology framework, we have established a closed-loop digital healthcare service model encompassing “intelligent matching – precision care – continuous optimization.” Through iterative technological upgrades and scenario expansion, we enable data-driven intelligent decision-making and operational refinement, significantly enhancing the quality and efficiency of medical, nursing, and health management services.

## **Scalable “Ningbo Model” Drives Nationwide Expansion of Platform Network**

Based on the mature experience of successful operation of the first city-specific cloud hospital platform of China in Ningbo, we have built a digital medical service system covering the whole chain of medical, nursing, health management, etc. The “Ningbo model” that has been verified by practice for more than ten years has a high degree of reproducibility, providing a standardized implementation path for national business expansion. By continuously deepening the application of AI technology and the construction of smart medical systems, and cooperating with the deep market cultivation in key regions such as East China, North China and South China, we have achieved rapid growth in the city-specific cloud hospital platform network, and significantly improved the platform coverage and service efficiency. As of June 30, 2025, the number of healthcare institutions connected to our platform network exceeded 36,000, including 3,303 hospitals (as of June 30, 2024: 2,654), representing a year-on-year increase of 24.5%. The platform had 147,000 registered physicians (as of June 30, 2024: 137,000), representing a year-on-year increase of 8.0%, and 145,000 registered nurses (with over five years of clinical experience, as of June 30, 2024: 108,000), representing a year-on-year increase of 34.1%.

## **Focusing on Core Business to Pioneer Growth in the “Internet + Care Service” Industry**

As the leading “Internet + Care Service” platform operator in China, we vigorously focused on our core strategic positioning of “Medical and Nursing Services Delivered to Home”. We continue to strengthen our collaborations with several provincial and municipal governments in China, among which, we helped the governments of Zhejiang Province and Henan Province to form and operate two provincial “Internet + Care Service” platforms. Meanwhile, we are actively expanding home nursing platforms in key cities such as Chongqing, Shenyang, Nanning, Xuancheng, and Changzhou, thus has established a synergistic development model of “Provincial Benchmark Demonstration + Rapid Municipal Replication.” During the Reporting Period, we achieved dual improvements in service efficiency and quality through intelligent and accurate resource allocation and AI full-process monitoring and quality control system by leveraging our AI-powered intelligent dispatch system, and the strategic business has developed strongly and grown significantly. The volume of home care services we provided exceeded 218,000 (same period of 2024: exceeded 142,000), representing a year-on-year increase of 53.1%. The volume of nursing consultation services we provided exceeded 166,000 (same period of 2024: exceeded 147,000), representing a year-on-year increase of 12.9%.

## **Platform Ecosystem and Specialty Operations Two-wheel Drive Value Maximization**

We are advancing the “Medical and Nursing Services Delivered to Home” strategy by deeply integrating AI and big data technologies to establish a full-scenario smart service platform that converges “Medical + Nursing + Health Management”. Through the synergistic combination of technological innovation and specialty-specific operations, we empower healthcare institutions, medical professionals, users, and industry chain partners — forging a collaborative and shared medical and health service ecosystem. Leveraging deep insights into specialized and refined needs, segmented user profiles, and multi-stakeholder value propositions, we continuously refine our in-home specialty medical and care solutions across obstetrics & gynecology, pediatrics, traditional Chinese medicine, rehabilitation medicine and neurology. By integrating premium ecosystem resources, we deliver personalized value-added services through Xikang Care’s professional capabilities and XiKang E-Mall’s diversified product portfolio. This dual approach not only enhances user engagement efficiency but also achieves deepened user value extraction via portfolio innovation within our platform ecosystem.

During the Reporting Period, anchored in our Cloud Hospital Platform model and core business strategy, we deeply integrated AI technologies into key service scenarios. Through continuous urban network expansion, innovative service portfolio development, standardized capability deployment and intelligent operational systems, we achieved substantial growth in business value. The optimization and improvement of operating efficiency and financial structure, as well as the continuous improvement of operating net cash flow, has forged a self-reinforcing virtuous cycle where Technology – Efficiency – Financials – Scale interact multidimensionally, laying a solid foundation for accelerated nationwide scaling replication and profitability.

The following table sets forth the revenue from each business segment during the Reporting Period:

	Six Months ended June 30,			
	2025		2024	
	Revenue	%	Revenue	%
	<i>(RMB in thousands, except for percentages)</i>			
Medical Services <sup>(Note 1)</sup>	69,827	39.1%	87,615	48.9%
Nursing Services <sup>(Note 2)</sup>	34,624	19.4%	24,478	13.7%
Health Management Services <sup>(Note 3)</sup>	74,154	41.5%	67,121	37.4%
<b>Total</b>	<b>178,605</b>	<b>100.0%</b>	<b>179,214</b>	<b>100.0%</b>

Notes:

1. Revenue generated from our medical services segment decreased by 20.3% to RMB69.8 million for the six months ended June 30, 2025 from RMB87.6 million for the six months ended June 30, 2024, mainly attributable to the implemented structural optimization of certain low-margin business units to maximize the use of existing resources to improve resource efficiency, as well as increasing competition in the market which has reduced project opportunities.
2. Revenue generated from our nursing services segment increased by 41.4% to RMB34.6 million for the six months ended June 30, 2025 from RMB24.5 million for the six months ended June 30, 2024, mainly attributable to the gradual demonstration of economies of scale of nursing services benefiting from our realization of rapid replication by market promotion and professional operation apart from enhancing operational efficiency through information technology, digitization and AI empowerment.
3. Revenue generated from our health management services segment increased by 10.5% to RMB74.2 million for the six months ended June 30, 2025 from RMB67.1 million for the six months ended June 30, 2024, mainly attributable to an increase in the volume of health management services.

## **Development of Three Major Business Segments**

Xikang Cloud Hospital adheres to the health needs of the residents, constantly deepens the collaborative synergy of “Medical + Nursing + Health Management” and continues to lead the development of China’s home medical and nursing market. Our business portfolio takes the city-specific cloud hospital platform as the carrier and builds a full-lifecycle service ecosystem. Our medical service business is dedicated to empowering medical institutions and their practitioners through digitalization, to help them provide patients with “seamless and integrated online and offline, in-and out-of-hospital” online medical services. Our nursing service business extends the nursing services to out-of-hospital scenarios through specialized and standardized systems, providing users with hospital-equivalent home care services and online nursing consultation services. Our health management service business provides individual and institutional users with full-cycle health management services through our self-operated medical institutions. Through the deep integration of these three core businesses, we continuously innovate to meet users’ holistic health needs, strengthen the full-spectrum industrial service ecosystem of our cloud hospital platform, and enhance its market competitiveness.

We leverage AI as our core technological engine to continuously advance a user-centric healthcare service system. Through deep technology integration and innovative scenario applications, we have established an intelligent product portfolio spanning health advisory, diagnostic intelligence, precision nursing and rehabilitation management. An AI-driven closed-loop service model for smart medical care, nursing and health management is established, achieving synergistic optimization of real-time service responsiveness, Intelligent resource allocation, personalized user experiences, thereby advancing healthcare services toward intelligent, precise, and human-centric evolution.

During the Reporting Period, we were determined to focus on our strategy of “Medical and Nursing Services Delivered to Home”, consolidated the leading position in the existing markets, strategically explored new regions and developed business growth points. Through the efficient synergy and integration of our three core business domains – Medical, Nursing, and Health management — we have significantly enhanced resource consolidation capabilities. In collaboration with our ecosystem partners, we co-develop full-cycle, multi-tiered healthcare service and product portfolios that focus on the diversified needs of users. By combining service compassion with clinical expertise, we drive dual empowerment: elevating user experiences while advancing commercial value creation.

### **Medical Services**

We insist on the seriousness of medical services, adhere to a patient-oriented approach, and constantly innovate to meet the patients’ inside-hospital to outside-hospital and offline-to-online medical service needs. By deeply integrating urban healthcare ecosystem resources, our city-specific cloud hospital platform provides users with high-quality, efficient, safe, reliable, and clinically equivalent home-based medical services. During the Reporting Period, we intensified our focus on specialty-specific operations for internet healthcare, further enhancing medical service delivery capacity. This enabled continuous extension of healthcare scenarios and expansion of medical resources, solidifying an increasingly mature urban medical service operational network.

With the rapid advancement of AI technologies in enabling precision and intelligence for medical services, we continuously upgrade our technological infrastructure through large-scale models and big data, delivering a digital-intelligent medical service system for both physicians and patients. For physicians, we provide the “Smart Medical Assistant” embedded across all stages of medical service chains, helping doctors enhance diagnostic and treatment efficiency, help medical institutions optimize patients’ medical treatment processes and improve overall clinical experience. For patients, we provide “Intelligent guidance” and “AI interpretation of diagnostic reports” and other tools. Leveraging AI, machine learning, and data analytics, we deeply analyze patient data, medical knowledge, and clinical guidelines. Through 24/7 full-time responsiveness, we precisely match patients with high-quality medical resources and service providers.

During the Reporting Period, to maximize the utilization of existing medical resources and enhance resource efficiency, we proactively implemented structural optimization adjustments to certain low-profit business units, resulting in a temporary decline in medical service volumes. The volume of internet medical services was 2,060,000 (same period of 2024: 2,231,000), representing a year-on-year decrease of 7.7%. Among them, the volume of our online consultation services was 942,000 (same period of 2024: 1,033,000), representing a year-on-year decrease of 8.8%. The volume of our e-prescription services was 394,000 (same period of 2024: 373,000), representing a year-on-year increase of 5.6%. The volume of examination services was 288,000 (same period of 2024: 249,000), representing a year-on-year increase of 15.7%. The volume of remote medical services was 436,000 (same period of 2024: 576,000), representing a year-on-year decrease of 24.3%. Through precisely fine-tuning the business structure, we further enhanced the operational quality of our medical services and paved the way for greater future development.

While focusing on optimizing patient experiences and advancing intelligent capabilities, we continuously enhanced our institutional service capacity. We consistently pursued technological iterations, service innovations on our cloud hospital platform, empowering clinical decision support and intelligent patient management. This has significantly strengthened the collaborative efficiency between the platform and medical institutions, markedly improved the convenience and precision of medical service delivery, and considerably deepened our engagement with both government (G-end) and hospital (H-end) clients, providing patients with more cost-effective healthcare services. As of June 30, 2025, we assisted 202 hospitals to establish their internet hospitals through our cloud hospital platform (same period of 2024: 165), representing a year-on-year increase of 22.4%.

During the Reporting Period, the revenue from our medical services business amounted to RMB69.8 million (same period of 2024: RMB87.6 million), representing a year-on-year decrease of 20.3%.



## Nursing Services

As an innovative leader in China's home-based medical care industry, we efficiently integrate healthcare resources through our "City-Specific Cloud Hospital Platform" model, accelerating the delivery of at-home medical services. Given that home care service is a serious medical service in China, which is subject to compulsory access management and process supervision by government authorities. Therefore, we have been firmly adhering to the core line of "official platform, regional layout", and complying with the principles of professionalism, safety and trustworthiness to maximize the satisfaction of users' needs for home and extended medical services. In 2016, we took the lead in launching an innovative pilot program for "home care service" in Ningbo City. Accumulated through long-term practice, we have formed a mature and comprehensive operational service system, and we took the opportunity of "Innovation in One Place, Sharing across the Province" in Ningbo as the starting point, to gradually facilitate the replication and expansion of our home care services throughout China. On account of continuous development and experience, we have accumulated a mature experience model and good market recognition in the home care industry and built the "Xikang Care (熙康護理)" brand, with business covering the East, Central, South and Southwest regions of China.

### Forging an Industry Benchmark for "Internet + Care Service" Driving Synergistic Growth with Regional Ecosystems

Committed to establishing sound standards and system of home care services, so as to establish a unified urban management system, service model, service standards, operation mechanism, training system to ensure that residents within the business coverage area can enjoy the high-quality and homogeneity of home care services. Centered on the "Care in Zhejiang (浙里護理)" platform, we implemented a province-wide networked management system spanning 664 medical institutions. By eliminating information silos among platforms, hospitals, and primary care facilities, we achieved seamless integration of resources and services, creating an integrated provincial nursing network that optimizes and efficiently utilizes healthcare resources across the province. Concurrently, we actively pursue horizontal integration strategies to deepen convergence between care services and other sectors. Through strengthened collaborations with government, financial, and insurance entities, we pioneered innovative models like nursing vouchers and commercial insurance payment solutions. These initiatives significantly lower accessibility thresholds for premium nursing services, expand business boundaries, and enable cross-sector resource sharing and complementary advantages.

We have fully undertaken the formation and operation of several provincial and municipal official "Internet + Care Service" regional-level platforms, established the home care service network covering Zhejiang, Henan, Chongqing, Liaoning, Guangxi, Anhui, Jiangsu, and other provinces/municipalities. During the Reporting Period, we deepened the service operation of home care platforms such as the "Care in Zhejiang (浙里護理)" in Zhejiang Province, the "YuJian Huli Daojia (豫健護理到家)" in Henan Province, the "Cloud Care in Chongqing (渝悅雲護理)" in Chongqing City, the "Kind Care (盛情護理)" in Shenyang City, Liaoning Province, the "Nanning Cloud Hospital for Home Care (南寧雲醫院居家護理)" in Nanning City, Guangxi Zhuang Autonomous Region, the "Care in Xuan (宣慧護理)" in Xuancheng City, Anhui Province, and the newly expanding platform "Care in Changzhou (常享護理)" in Changzhou City, Jiangsu Province, with covered population growing steadily over 0.2 billion. Among which, the "YuJian Huli Daojia (豫健護理到家)" platform, launched in the first half of 2024, is expanding its reach across Henan Province. As of June 30, 2025, 553 medical institutions (as of June 30, 2024: 391) and 53,000 nurses (with more than 5 years of clinical nursing experience, as of June 30, 2024: 31,000) have joined the platform, representing a year-on-year increase of 41.4% and 70.9%, respectively.

Moving forward, we will continue to advance our dual-track strategy of “regional penetration + nationwide expansion”. We are committed to continuously enhancing our service infrastructure and extending our coverage, bringing convenient and professional home care services to more households across China.

### **AI-Enabled Professional Operations Driving Comprehensive Enhancement of Home Care Services**

Currently, we have established a standardized operating system demonstrating high replicability and adaptability. Through standardized process architecture and intelligent technology enablement, we deepen professional operating capabilities and have built precision operations models to achieve granular market penetration in existing regions while enabling rapid replication in new markets by leveraging AI and big data. In the meanwhile, we strengthen data operations and dynamically optimize service resource allocation by analyzing user behavior and predicting demand patterns. This enhances user engagement, accelerates conversion rates, and delivers substantial growth in paying nursing care subscribers.

Centered around user needs and based on building a standardized management system, we have comprehensively upgraded the home care service platform. By deeply integrating technologies such as Natural Language Processing (NLP) and multimodal interaction, we successfully launched the nursing AI agent “Xiaoxi Assistant.” This forms a service closed-loop covering intelligent prediction, precise matching, and dynamic optimization. Furthermore, we established a three-in-one smart customer service system comprising “AI Smart Customer Service + Enterprise WeChat + Customer Service Hotline,” achieving seamless transition from user inquiry to issue resolution. This has significantly enhanced service efficiency and user experience.” As of June 30, 2025, the volume of home care services we provided exceeded 218,000 (same period of 2024: exceeded 142,000), representing a year-on-year increase of 53.1%.

Amid increasing specialization in healthcare services, we have dedicated strategic focus to pioneering innovations within specialized nursing segments while expanding service coverage. Targeting core demographic groups – particularly the elderly, maternal and child populations, chronic disease patients, and post-operative recovery cohorts – we have integrated professional care with intelligent technologies to develop a diversified solution portfolio spanning in-home nursing, rehabilitation services, and medical equipment leasing scenarios. Relying on accurate insights into user needs, we continue to optimize the content and form of services, not only providing basic nursing support, but also extending to specialized medical care, rehabilitation assistance and other professional fields, forming a multi-level and multi-dimensional service ecology, and gradually realizing the upgrade from single nursing to full-cycle health management. As of June 30, 2025, the number of our service items expanded to 220+ (as of December 31, 2024: 200+).

During the Reporting Period, the revenue from our nursing service business amounted to RMB34.6 million (same period of 2024: RMB24.5 million), representing a year-on-year increase of 41.4%.

### **Health Management Services**

We adhere to building an integrated “health and medical” service system from offline to online by focusing on the health of users, and are dedicated to providing users with continuous, closed-loop health management solutions spanning the entire lifecycle. During the Reporting Period, leveraging our 9 medical institutions in 9 cities across the country and the integration advantages of “Medical + Nursing + Health Management” resources, we have established a seamless connection of “products + services” ecosystem. This enables us to deliver diversified, integrated service solutions for both institutional and individual clients.



Capitalizing on efficient business synergies, extensive resource integration, and strong brand recognition, we have deepened our exploration on the requirements of health management scenarios. Anchored by our physical examination services and incorporating cutting-edge technologies such as genetic testing and functional medicine, we deliver one-stop services spanning disease screening to precision diagnostics. This approach has further strengthened service synergies, enabled the development of our distinctive “1+N” Health Management Service Model while continuously exploring new businesses. During the Reporting Period, we comprehensively strengthened ecosystem synergies across our health management services. Through strategic collaboration with specialized third-party diagnostic institutions, we advanced an integrated online-to-offline (O2O) health management solution for “Precision Testing + Precision Nutrition” leveraging genetic testing and big data analytics, driving marked enhancement in service quality.

We continuously intensified the application of multimodal data analytics and AI technologies, upgrading core functionalities including intelligent physical examination interpretation and health record management. We innovatively launched digital tools such as the “Kang AI Assistant” intelligent analytics system and the “Whole-Body Health Map”, enabling end-to-end intelligent tracking across health assessment, intervention planning, and outcome monitoring. This has allowed us to build a technology-infused health management service framework, comprehensively enhancing precision and intelligence levels in health management while elevating user value perception. During the Reporting Period, the volume of our health management services amounted to 205,000 (same period of 2024: amounted to 160,000), representing a year-on-year increase of 28.1%.

During the Reporting Period, the revenue from our health management service business amounted to RMB74.2 million (same period of 2024: RMB67.1 million), representing a year-on-year increase of 10.5%.

## **II. BUSINESS PROSPECTS**

Against the backdrop of intensifying demographic pressures from population aging and declining birth rates, China’s healthcare industry is undergoing profound transformation. Sustained expansion of market demand, accelerated policy tailwinds, and continuous technological empowerment are collectively ushering in exceptional opportunities and challenges across the sector. As the pioneer of the city-specific cloud hospital model and the leader in serious medical digital transformation in China, we will keep up with the core trends of the internet healthcare in “AI + Whole Course Management” and “Inclusive Home Medical” services. We will adhere to our business development strategy empowered by “the providers, the demanders, the payers and the regulators”, and accelerate the construction of the nationwide “Medical and Nursing Services Delivered to Home” network and ecosystem. While ensuring the compliance, safety and professionalism of the services provided on the platform, we are driving boundaryless connectivity of medical resources, precision enhancement of service capabilities, and systematic value realization across the healthcare industry through technological innovation and model optimization. These initiatives ultimately position us as a core enabler of next-generation medical infrastructure.

Leveraging our first-mover advantage in “Internet + Care Service” and validated standardized operational systems, we will accelerate the deployment and expansion of our city-specific cloud hospital platform within the smart healthcare ecosystem. This initiative delivers professional, secure, and comprehensive medical and nursing services to households nationwide with targeted precision, while continuously enhancing resource-demand alignment efficiency. We are developing diversified, scenario-specific home medical and nursing services and delivery formats to establish a scalable service network, accelerating the market conversion efficiency of diversified resources, continuously amplifying economies of scale, and achieving dual enhancement of societal and commercial value.

We will deeply integrate AI and big data technologies to comprehensively upgrade our “Medical and Nursing Services Delivered to Home” ecosystem. By focusing on multimodal AI capabilities, we are building an intelligent closed-loop management system covering the entire disease course spanning prevention, treatment, and rehabilitation. Powered by end-to-end data accumulation, our dynamically optimized intelligent data platform will drive healthcare’s evolution from reactive treatment to proactive health management, from hospital-centric to precision beyond-hospital and home-based settings, from basic care to specialized and personalized solutions. This technology-driven, data-empowered transformation will achieve service precision, process leanness, and sustained product innovation, advancing our core business’s efficient and sustainable development.

We are committed to transcending spatiotemporal constraints of traditional healthcare models, establishing ourselves as ecosystem architects and value enablers in the new medical economy. Through deep integration into the health and wellness industry landscape, we facilitate cross-sector resource synergies while expanding the scope of “Online + At-Home” healthcare services. These initiatives activate new momentum in the silver economy and advance sustainable industrial ecosystem development. We take the City-Specific Cloud Hospital platform and its accumulated “Medical + Nursing + Health Management Services” business resources as the foundation to construct an integrated one-stop medical service ecosystem. This model drives deep integration across governments, medical institutions, commercial insurers, pharmaceutical supply chains, and health management providers – establishing a closed-loop “Care + Payment + Supply Chain + Data” architecture to better serve our C-end users.

Leveraging our City-Specific Cloud Hospital Platform to redefine supply efficiency and professionalized services to secure safety baselines, we have pioneered an arduous yet right and inclusive development path — validated by industry evolution, policy endorsement, and user trust. We are confident that through technological empowerment, ecosystem collaboration, and model innovation, we are striving tirelessly to achieve the vision of “empowering every family with fair, precise, friendly medical, nursing, and home care services.” This commitment positions our premium at-home medical care as an essential health safeguard for multitudes of Chinese families.

## **FINANCIAL REVIEW**

### **Revenue from Contracts with Customers**

Our revenue decreased by 0.3% to RMB178.6 million for the six months ended June 30, 2025 from RMB179.2 million for the six months ended June 30, 2024, mainly attributable to a decrease in revenue from medical services.

#### **Medical services**

Revenue generated from our medical services segment decreased by 20.3% to RMB69.8 million for the six months ended June 30, 2025 from RMB87.6 million for the six months ended June 30, 2024, mainly attributable to the implemented structural optimization of certain low-margin business units to maximize the use of existing resources to improve resource efficiency, as well as increasing competition in the market which has reduced project opportunities.

#### **Nursing services**

Revenue generated from our nursing services segment increased by 41.4% to RMB34.6 million for the six months ended June 30, 2025 from RMB24.5 million for the six months ended June 30, 2024, mainly attributable to the gradual demonstration of economies of scale of nursing services benefiting from our realization of rapid replication by market promotion and professional operation apart from enhancing operational efficiency through information technology, digitization and AI empowerment.

#### **Health management services**

Revenue generated from our health management services segment increased by 10.5% to RMB74.2 million for the six months ended June 30, 2025 from RMB67.1 million for the six months ended June 30, 2024, mainly attributable to an increase in the volume of health management services.

### **Cost of Sales and Services**

Our cost of sales and services increased by 1.9% to RMB139.3 million for the six months ended June 30, 2025 from RMB136.7 million for the six months ended June 30, 2024, mainly attributable to an increase in revenue of nursing services and health management services.

### **Gross Profit and Gross Margin**

As a result of the foregoing, our gross profit decreased by 7.6% to RMB39.3 million for the six months ended June 30, 2025 from RMB42.6 million for the six months ended June 30, 2024.

During the Reporting Period, the gross margins of medical services, nursing services and health management services were 13.3%, 19.1% and 31.6%, respectively (same period of 2024: 17.7%, 26.6% and 30.5%). Our gross margin decreased to 22.0% for the Reporting Period from 23.7% for the six months ended June 30, 2024, mainly attributable to the high proportion of revenue from medical services, and the gross profit margin of such sector has declined as compared to the same period last year, resulting in a decline in the Company's overall gross profit margin.

## **Selling and Distribution Expenses**

Our selling and distribution expenses decreased by 17.0% to RMB31.0 million for the six months ended June 30, 2025 from RMB37.3 million for the six months ended June 30, 2024, mainly attributable to the continuous strengthening of production control and the constant improvement of resource allocation efficiency.

## **Research and Development Expenses**

Our research and development expenses decreased by 8.0% to RMB19.6 million for the six months ended June 30, 2025 from RMB21.3 million for the six months ended June 30, 2024, mainly attributable to the continuous strengthening of production control and the constant improvement of resource allocation efficiency.

## **Administrative Expenses**

Our administrative expenses decreased by 1.0% to RMB43.3 million for the six months ended June 30, 2025 from RMB43.7 million for the six months ended June 30, 2024, mainly attributable to the continuous optimization of organizational effectiveness, resulting in a decrease in manpower and related expenses.

## **Other Income**

Our other income decreased by 74.3% to RMB3.3 million for the six months ended June 30, 2025 from RMB12.8 million for the six months ended June 30, 2024, mainly attributable to a decrease in government grants and investment income from wealth management products.

## **Other Gains, Net**

We recorded net other gains of RMB0.4 million for the six months ended June 30, 2024, compared to the net other gains of RMB4.9 million for the six months ended June 30, 2025, primarily due to an increase in gains from the disposal of associates.

## **Finance Income and Finance Costs**

Our finance costs after deducting net finance income increased by 12.2% to RMB6.2 million for the six months ended June 30, 2025 from RMB5.5 million for the six months ended June 30, 2024, mainly attributable to a decrease in interest income.

## **Share of Losses of Associates**

Our share of losses of associates decreased by 5.2% to RMB4.7 million for the six months ended June 30, 2025 from RMB4.9 million for the six months ended June 30, 2024, mainly attributable to a decrease in losses of associates.

## **Income Tax Credit**

We recorded income tax credit of RMB0.3 million for the six months ended June 30, 2025, compared to income tax credit of RMB0.1 million for the same period of 2024, mainly attributable to an increase in deferred income tax credit.

## Loss for the Period

As a result of the foregoing, our loss for the Reporting Period decreased by 17.4% to RMB50.0 million for the six months ended June 30, 2025 from RMB60.5 million for the six months ended June 30, 2024.

## Adjusted Net Loss

To supplement our consolidated statements of profit or loss which are presented in accordance with HKFRS, we use adjusted net loss for the Reporting Period (non-HKFRS measure) as non-HKFRS measures, which are not required by, or presented in accordance with, HKFRS. We believe that the presentation of such non-HKFRS measures when shown in conjunction with the corresponding HKFRS measures provides useful information to potential investors and management in facilitating a comparison of our operating performance from period to period by eliminating potential impacts of certain items, such as share-based compensation expenses. The use of the non-HKFRS measures has limitations as an analytical tool, and investors should not consider it in isolation from, or as a substitute for or superior to, the analysis of our results of operations or financial condition as reported under HKFRS. In addition, the non-HKFRS measures may be defined differently from similar terms used by other companies.

The following table reconciles our adjusted net loss for the period (non-HKFRS measure) to the most directly comparable financial measure in accordance with HKFRS for the periods indicated:

	<b>For the six months ended June 30,</b>	
	<b>2025</b>	<b>2024</b>
	<i>(RMB in millions, except for percentages)</i>	
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Loss for the period	<b>(49,975)</b>	(60,484)
Add: Share-based compensation expenses	<b>11,571</b>	9,182
Adjusted net loss for the period (non-HKFRS measure)	<b>(38,404)</b>	(51,302)

The non-HKFRS measure, adjusted net loss for the period, used by us has been adjusted for share-based compensation expenses. In particular, the share-based compensation expenses are non-cash expenses arising from granting share-based awards to selected employees.

Our adjusted net loss (non-HKFRS measure) decreased by 25.1% from RMB51.3 million for the six months ended June 30, 2024 to RMB38.4 million for the six months ended June 30, 2025. The decrease in our adjusted net loss (non-HKFRS measure) for the six months ended June 30, 2025 was mainly due to (i) during the Reporting Period, the Group's nursing services gradually demonstrated economies of scale, effectively improving organizational effectiveness and resource allocation efficiency, and enhancing operational efficiency through information technology, digitization and AI empowerment, which resulted in a significant decrease in expenses; and (ii) a decrease in net impairment losses on financial assets resulting from the recovery of trade receivables.



## **Contingent Liabilities**

As of June 30, 2025, we were not involved in any material legal, arbitration or administrative proceedings that were expected to materially and adversely affect our financial condition or results of operations, although there can be no assurance that this will not be the case in the future.

As of June 30, 2025, we did not have any significant contingent liabilities (as of December 31, 2024: nil).

## **Capital Expenditures**

During the Reporting Period, we incurred capital expenditures of RMB4.1 million mainly for purchases of property, plant and equipment (for the six months ended June 30, 2024: RMB4.4 million).

## **Pledge of Assets**

As of June 30, 2025, the Group did not pledge any assets.

## **Future Plans for Material Investments or Capital Assets**

Save as disclosed under the section headed “Proceeds from the Global Offering” herein, as of June 30, 2025, the Group did not have any other plans for material investments or capital assets.

## **Liquidity and Capital Resources**

Historically, we have funded our working capital primarily from bank borrowings and equity financing. As of June 30, 2025, we had cash and cash equivalents of RMB490.8 million. We expect to use a portion of the proceeds from the Global Offering (within the meaning of the Prospectus of the Company dated September 18, 2023) to fund our working capital requirements. We currently do not have any plans for material additional external financing.

The following table sets forth our cash flows for the periods indicated:

	<b>For the six months ended June 30,</b>	
	<b>2025</b>	<b>2024</b>
	<i>(RMB in thousands, except for percentages)</i>	
	<b>(unaudited)</b>	<b>(unaudited)</b>
Cash used in operating activities	<b>(52,376)</b>	(66,726)
Interest received	<b>5,336</b>	8,128
Income taxes paid	<b>(2,921)</b>	(5,708)
Net cash used in operating activities	<b>(49,961)</b>	(64,306)
Net cash used in investing activities	<b>(147,517)</b>	(6,519)
Net cash used in financing activities	<b>(70,843)</b>	(33,783)
Net decrease in cash and cash equivalents	<b>(268,321)</b>	(104,608)
Cash and cash equivalents at the beginning of the period	<b>760,857</b>	676,794
Effects of exchange rate changes on cash and cash equivalents	<b>(1,747)</b>	3,744
Cash and cash equivalents at the end of the period	<b>490,789</b>	575,930

### **Net cash used in operating activities**

Our cash flows from operating activities reflect: (i) cash used in operating activities; and (ii) other cash items (such as interest received and income tax paid).

For the six months ended June 30, 2025, we had net cash used in operating activities of RMB50.0 million, which represents our cash used in operating activities of RMB52.4 million and other cash items of RMB2.4 million.

### **Net cash used in investing activities**

For the six months ended June 30, 2025, we had net cash used in investing activities of RMB147.5 million, which was mainly attributable to (i) subscription amount for our wealth management products of RMB395.0 million, partially offset by the redemption amount for our wealth management products of RMB251.4 million; and (ii) purchase of property, plant and equipment of RMB4.1 million.

### **Net cash used in financing activities**

For the six months ended June 30, 2025, we had net cash used in financing activities of RMB70.8 million, which was mainly attributable to (i) repayments of borrowings of RMB290.8 million, partially offset by proceeds from bank borrowings of RMB244.0 million; (ii) payments of lease liabilities of RMB11.3 million; and (iii) payments of interest of RMB10.4 million.

### **Borrowings**

As of June 30, 2025, the aggregate principal balance of our borrowings was RMB463.1 million (as of December 31, 2024: RMB509.9 million). As of June 30, 2025, RMB30.7 million of our banking facilities remained unutilized (as of December 31, 2024: RMB0.1 million).

As of June 30, 2025, all of our non-current borrowings and substantially all of our current borrowings were bank loans. The maturity dates of our outstanding borrowings fall on or before June 2026.

## Significant Investments Held

During the Reporting Period, the details of any significant investments held by the Company are as follows:

Name of the investee company	Principal business	As at June 30, 2025			Percentage of total assets of the Group	For the six months ended June 30, 2025	
		Investment cost (RMB'000)	Shareholding percentage	Carrying amount (RMB'000)		Dividend distributed (RMB'000)	Investment loss in associates (RMB'000)
Neusoft Management Consulting (Shanghai) Co., Ltd.	Business consulting service, including, among others, medical devices	96,436	49.00%	85,330	7.68%	–	(1,190)

### Note:

The Group's significant investment in an associate set out above was made before the Listing Date and held during the Reporting Period. Investments in an associate are accounted for using the equity method of accounting, after initially being recognised at cost. The associate is an unlisted company, and there is no quoted price or fair value available.

Neusoft Management Consulting (Shanghai) Co., Ltd. mainly holds a property, which is used by the Group to provide health management services. Accordingly, the Directors believe that investments in Neusoft Management Consulting (Shanghai) Co., Ltd. could bring synergistic effects to our Group, which is conducive to our future development.

For the six months ended 30 June 2025, the Group subscribed for wealth management products issued by Shenwan Hongyuan Financial Products with its idle Proceeds from the Global Offering as part of the Group's cash management to improve the efficiency of capital utilization, increase capital income, and achieve the preservation and appreciation of the Proceeds while maintaining security and flexibility. As at 30 June 2025, the amount of wealth management products held by the Group was US\$20.1 million, with a fair value of US\$20.2 million, and the fair value as a percentage of the Group's total assets was 13.0%, and the unrealised gain or loss was US\$0.1 million during the Reporting Period.

Save as disclosed above, during the Reporting Period, the Company did not hold any other significant investments (including any investment in an investee company with a value of 5% or more of the Group's total assets as at June 30, 2025).

## Capital Commitments

As of June 30, 2025, we did not have any material capital commitments.

## **Material Acquisition and Disposal of Subsidiaries, Associates and Joint Ventures**

On May 20, 2025, (i) Xikang Health Technology Co., Ltd. (Xikang Health Technology), a wholly-owned subsidiary of the Company, Neutech Group Limited (Neutech), and Dalian Xikang Yunshe Kang Travel Investment Management Co., Ltd. (Dalian Yunshe) entered into the Equity Transfer Agreement, pursuant to which, Xikang Health Technology disposed of the registered capital of Dalian Yunshe of RMB32,757,364 held by Xikang Health Technology, representing approximately 4.23% of total share capital of Dalian Yunshe, for a consideration of RMB30 million; and (ii) Neutech and Dalian Yunshe entered into the Capital Increase Agreement, pursuant to which, the registered capital of Dalian Yunshe will be increased by RMB49,136,047. Following the completion of the equity transfer and capital increase arrangement, the Company holds the registered capital of Dalian Yunshe of RMB58,982,636, representing approximately 7.15% of the total share capital of Dalian Yunshe.

For further details, please refer to the Company's announcement dated May 20, 2025.

Save as disclosed above, our Company did not have any material acquisition or disposal of subsidiaries, associates and joint ventures during the Reporting Period.

## **RISK MANAGEMENT**

### **Foreign Exchange Risk**

Foreign exchange risk arises when future commercial transactions or recognized assets and liabilities are denominated in a currency that is not the Group entities' functional currency. The functional currencies of our Company and the subsidiaries operating in the PRC are the US dollar and Renminbi, respectively. We manage our foreign exchange risk by performing regular reviews of our net foreign exchange exposures and try to minimize these exposures through natural hedges, wherever possible, and may enter into forward foreign exchange contracts, when necessary.

We operate mainly in the PRC with most of the transactions settled in Renminbi. Our management considers that our business is not exposed to any significant foreign exchange risk as we have no significant financial assets or liabilities denominated in currencies other than the respective functional currencies of our entities. As of June 30, 2025, our Company did not hold any financial instruments for hedging purposes.

### **Gearing Ratio**

The Group monitors capital on the basis of the gearing ratio. This ratio is calculated as net debt divided by total equity. Net debt is calculated as total liabilities, which are considered as borrowings and total lease liabilities less cash and cash equivalents. As at June 30, 2025, the gearing ratio of the Group was 9.3% (the gearing ratio is not applicable as the Group recorded a net cash position as at December 31, 2024).

### **Cash Flow and Fair Value Interest Rate Risk**

Our income and operating cash flows are substantially independent of changes in market interest rates and we have no significant interest-bearing assets except for the investments in wealth management products.

## PURCHASE, SALE OR REDEMPTION OF OUR COMPANY’S LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company’s securities listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (including sale of treasury shares). As of the end of the Reporting Period, the Company did not hold treasury shares.

## EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2025, the Company had 834 full-time employees, all of whom are based in China. The following table sets forth the breakdown of the Company’s employees by function as of June 30, 2025:

Function	Number of Employees	% of Total
Management and administration	138	16.5
Sales and marketing and operational support	204	24.5
Research and development	151	18.1
Health management	341	40.9
<b>Total</b>	<b>834</b>	<b>100.0</b>

As of June 30, 2025, the compensation and benefits expenses of the Company paid to its employees were RMB74.9 million (for the six months ended June 30, 2024: RMB86.6 million). Among all of the Company’s 834 employees, 459 employees had bachelor’s degrees or above, accounting for 55.0% of the Company’s total employees.

The Company is committed to establishing competitive and fair remuneration. In order to effectively motivate the Company’s employees, the Company continually refines its remuneration and incentive policies through market research. The Company conducts performance evaluations for employees semi-annually to provide feedback on their performance. Compensation for employees typically consists of a basic salary and a performance-based bonus. We also adopted two share option schemes to enhance the enthusiasm, sense of responsibility and sense of mission of our employees, and thereby coordinate the interests of our employees with the interests of our Company.

We provide social insurance plans and housing provident funds to our employees in accordance with applicable PRC laws and regulations. We pay great attention to our employees’ welfare, and continually improve our welfare system. We offer employees additional benefits such as annual leave, stipend, supplementary medical insurance, health examinations and medical insurance for family members, among other things.

The Group provides employees with adequate job training to equip them with practical knowledge and skills. The Company also conducts introductory training for new staff.

As of the date of this results announcement, the Company did not have any strikes, protests or other material labor conflicts that may materially impair the Company’s business and image.



## EVENTS AFTER THE REPORTING PERIOD

Under the Post-IPO Share Option Schemes, the Company granted an aggregate of 28,990,000 share options to 236 eligible participants (the “**Grantee(s)**”) on July 21, 2025 to subscribe for shares with a par value of US\$0.0002 each in the share capital of the Company. The grantee includes Ms. ZONG Wenhong, an executive Director and Chief Executive Officer of the Company, who was granted 5,000,000 share options. The remaining grantees are employees of the Company. The exercise price of the share options is HK\$0.904.

For further details, please refer to the Company’s announcement dated July 21, 2025.

## COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company has adopted the code provisions of the Corporate Governance Code (the “**CG Code**”) contained in Appendix C1 to the Listing Rules as the basis for the Company’s corporate governance practices. The Company is committed to implementing the best corporate governance practices.

The Company has complied with the code provisions under the CG Code during the Reporting Period and up to the date of this results announcement.

## PROCEEDS FROM THE GLOBAL OFFERING

On September 28, 2023 (the “**Listing Date**”), the Shares of our Company were listed on the Main Board of the Stock Exchange, with a total of 133,805,500 Shares issued at an offer price of HK\$4.76. The net proceeds from the Global Offering (the “**Proceeds**”), after deducting the underwriting commissions and other offering expenses payable by us in connection with the Global Offering, were approximately HK\$554.5 million (the over-allotment option was not exercised), which will be used in accordance with the use of Proceeds as disclosed in the Prospectus from the Listing Date as follows:

- approximately 30% of the net Proceeds, for expansion of city-specific cloud hospital platforms to enlarge our medical networks and user base;
- approximately 25% of the net Proceeds, for enriching our offerings across the industry value chain to provide more professional and diversified healthcare services;
- approximately 25% of the net Proceeds, for research and development on technology infrastructure and data capabilities;
- approximately 10% of the net Proceeds, for potential mergers and acquisitions opportunities;
- approximately 10% of the net Proceeds, for working capital and other general corporate purposes.

As of June 30, 2025, the Group's use of the net Proceeds is set out in the table below:

Purpose of use	% of use of Proceeds	Net Proceeds (HK\$ million)	Unutilized amount as at January 1, 2025 (HK\$ million)	Utilized amount for the six months ended June 30, 2025 (HK\$ million)	Unutilized amount as at June 30, 2025 (HK\$ million)	Expected timetable for utilization
Expansion of city-specific cloud hospital platforms to enlarge our medical networks and user base	30%	166.3	150.1	13.9	136.2	By December 31, 2028
Enriching our offerings across the industry value chain to provide more professional and diversified healthcare services	25%	138.6	128.5	6.4	122.1	By December 31, 2028
Research and development on technology infrastructure and data capabilities	25%	138.6	117.7	19.7	98.0	By December 31, 2028
Potential mergers and acquisitions opportunities	10%	55.5	55.5	0.0	55.5	By December 31, 2028
Working capital and other general corporate purposes	10%	55.5	44.7	7.7	37.0	By December 31, 2028

In order to improve the fund utilization efficiency, reasonably utilize the temporarily idle Proceeds, realize value preservation and appreciation of the Proceeds, and protect the interest of shareholders of the Company, the Board respectively resolved on June 13, 2024 and 2025 that, without prejudice to the normal operating activities of the Company, the Proceeds that are expected to remain idle for more than one year are intended to be used in proper purchases of wealth management products that feature high security, sound liquidity, and can be redeemed at any time, and the amount shall be no more than US\$40 million (the equivalent of approximately HK\$312.4 million and HK\$314.0 million, respectively, calculated based on the exchange rate published by the People's Bank of China as at the date of relevant Board meeting), for cash management purpose. Such amount can be utilized on a rolling basis within 12 months from the date of the relevant Board's resolution. The return from cash management is accounted to the Company, which will not affect in substance the normal use of the Proceeds in accordance with the intended purposes as disclosed in the Prospectus and the normal operations of the Company. The Board believes that cash management is in the interest of the Company and its shareholders as a whole.

The subscription of wealth management products pursuant to the aforementioned amount may constitute a notifiable transaction under Chapter 14 and/or a connected transaction under Chapter 14A of the Listing Rules in the future, the Company has complied and will continue to comply with the relevant requirements under the Listing Rules.

## INTERIM DIVIDEND

The Board has resolved not to recommend the distribution of an interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: nil).

## COMPLIANCE WITH THE MODEL CODE

From the Listing Date, the Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as its code of conduct for securities transactions by Directors.

Having made specific enquiries to all of the Directors, all Directors confirmed that they have fully complied with all relevant requirements set out in the Model Code during the Reporting Period and up to the date of this results announcement.

## SCOPE OF WORK OF AUDITOR

The figures contained in the Group’s interim condensed consolidated statement of financial position, interim condensed consolidated statement of profit or loss and other comprehensive income and related notes for the six months ended June 30, 2025 as set out in this results announcement have been agreed by the Group’s auditors, Ernst & Young, in line with the amounts set out in the Group’s unaudited interim financial statement. The work performed by Ernst & Young in this respect did not constitute an assurance engagement, and consequently no assurance has been expressed by Ernst & Young on this announcement.

## AUDIT COMMITTEE

The Audit Committee (the “**Audit Committee**”) of our Company comprises three independent non-executive Directors, namely Dr. CHEN Yan, Dr. QI Guoxian and Dr. YIN Guisheng. Dr. CHEN Yan is the chairwoman of the Audit Committee. The Audit Committee of our Company has reviewed the interim results of our Company for the six months ended June 30, 2025.

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2025

	Notes	2025 <b>RMB'000</b> (Unaudited)	2024 <b>RMB'000</b> (Unaudited)
<b>REVENUE</b>	4	<b>178,605</b>	179,214
Cost of sales		<u>(139,292)</u>	<u>(136,658)</u>
<b>Gross profit</b>		<u><b>39,313</b></u>	<u>42,556</u>
Selling and distribution expenses		(31,008)	(37,345)
Research and development expenses		(19,570)	(21,270)
Administrative expenses		(43,268)	(43,727)
Reversal of impairment losses/(impairment losses) on financial and contract assets, net		7,781	(3,619)
Other income	4	3,293	12,831
Other expenses		(866)	—
Other gains, net		4,921	417
Finance income	6	5,715	8,498
Finance costs	6	(11,933)	(14,041)
Share of losses of associates		<u>(4,670)</u>	<u>(4,927)</u>
<b>LOSS BEFORE TAX</b>	5	<u><b>(50,292)</b></u>	<u>(60,627)</u>
Income tax credit	7	<u>317</u>	<u>143</u>
<b>LOSS FOR THE PERIOD</b>		<u><u><b>(49,975)</b></u></u>	<u><u>(60,484)</u></u>

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND  
OTHER COMPREHENSIVE INCOME (Continued)**

*For the six months ended 30 June 2025*

	<i>Note</i>	<b>2025</b> <b>RMB'000</b> <b>(Unaudited)</b>	2024 <b>RMB'000</b> <b>(Unaudited)</b>
<b>OTHER COMPREHENSIVE INCOME/(LOSS)</b>			
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods			
Exchange differences:			
Exchange differences on translation of a foreign operation		<u>165</u>	<u>(622)</u>
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods		<u>165</u>	<u>(622)</u>
Other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods:			
Exchange differences:			
Exchange differences on translation of the Company's financial statements into presentation currency		<u>(2,741)</u>	<u>4,758</u>
Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods		<u>(2,741)</u>	<u>4,758</u>
<b>OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX</b>		<u>(2,576)</u>	<u>4,136</u>
<b>TOTAL COMPREHENSIVE LOSS FOR THE PERIOD</b>		<u><b>(52,551)</b></u>	<u><b>(56,348)</b></u>
<b>Loss attributable to:</b>			
Owners of the parent		<u>(48,886)</u>	<u>(59,559)</u>
Non-controlling interests		<u>(1,089)</u>	<u>(925)</u>
		<u><b>(49,975)</b></u>	<u><b>(60,484)</b></u>
<b>Total comprehensive loss attributable to:</b>			
Owners of the parent		<u>(51,462)</u>	<u>(55,423)</u>
Non-controlling interests		<u>(1,089)</u>	<u>(925)</u>
		<u><b>(52,551)</b></u>	<u><b>(56,348)</b></u>
<b>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b>			
Basic and diluted (RMB)	8	<u><b>(0.06)</b></u>	<u><b>(0.07)</b></u>



**INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**30 June 2025**

	<i>Notes</i>	<b>30 June 2025 RMB'000 (Unaudited)</b>	<b>31 December 2024 RMB'000 (Audited)</b>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	9	28,218	31,684
Right-of-use assets	10	53,430	60,689
Intangible assets		2,639	2,532
Investments in associates	11	85,330	169,559
Equity investments designated at fair value through other comprehensive income		54,018	–
Long-term trade receivables	12	3,314	5,860
Other receivables		2,982	3,251
Prepayments		326	–
Deferred tax assets		7,918	6,950
<b>Total non-current assets</b>		<b>238,175</b>	<b>280,525</b>
<b>CURRENT ASSETS</b>			
Inventories		20,649	17,268
Assets recognised from costs to fulfil contracts		7,826	6,000
Trade receivables	13	87,799	101,974
Contract assets		5,532	6,217
Prepayments		6,560	7,557
Other receivables		65,608	35,309
Other current assets		6,547	7,873
Financial assets at fair value through profit or loss		181,167	36,842
Restricted deposits		–	12
Cash and cash equivalents		490,789	760,857
<b>Total current assets</b>		<b>872,477</b>	<b>979,909</b>
<b>CURRENT LIABILITIES</b>			
Trade payables	14	162,721	201,137
Contract liabilities		31,814	29,013
Other payables and accruals		47,645	63,923
Interest-bearing bank borrowings		463,606	510,305
Lease liabilities		24,270	24,326
Tax payables		1,028	2,660
Other current liabilities		76	66
<b>Total current liabilities</b>		<b>731,160</b>	<b>831,430</b>
<b>NET CURRENT ASSETS</b>		<b>141,317</b>	<b>148,479</b>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>379,492</b>	<b>429,004</b>

**INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**(Continued)**  
30 June 2025

	<b>30 June 2025 RMB'000 (Unaudited)</b>	<b>31 December 2024 RMB'000 (Audited)</b>
<b>NON-CURRENT LIABILITIES</b>		
Contract liabilities	15,374	14,145
Lease liabilities	32,966	39,839
Deferred income	4,420	4,420
Deferred tax liabilities	1,840	2,478
	<hr/>	<hr/>
<b>Total non-current liabilities</b>	<b>54,600</b>	<b>60,882</b>
	<hr/>	<hr/>
<b>Net assets</b>	<b>324,892</b>	<b>368,122</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>EQUITY</b>		
<b>Equity attributable to owners of the parent</b>		
Share capital	1,125	1,125
Share premium	2,543,431	2,543,431
Reserves	367,035	359,083
Accumulated losses	(2,589,216)	(2,540,330)
	<hr/>	<hr/>
	322,375	363,309
<b>Non-controlling interests</b>	<b>2,517</b>	<b>4,813</b>
	<hr/>	<hr/>
<b>Total equity</b>	<b>324,892</b>	<b>368,122</b>
	<hr/> <hr/>	<hr/> <hr/>

# NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2025

## 1. GENERAL INFORMATION

Xikang Cloud Hospital Holdings Inc. (the “Company”) was incorporated in the Cayman Islands on 12 May 2011 as an exempted company with limited liability under the Companies Law (Cap. 22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company’s registered office is PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands.

The Company, an investment holding company, and its subsidiaries (together, the “Group”) are principally engaged in the provision of the following services: (i) medical services; (ii) nursing services; and (iii) health management services in the People’s Republic of China (the “PRC”).

## 2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICES

### 2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with HKAS 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2024.

The Company does not have legal ownership in the equity of certain entities. However, under certain contractual agreements (including power of attorney agreement, loan agreement, equity option agreement, equity interest pledge agreement and exclusive technical consulting and services agreement) entered into with the registered owners of the entities, the Company through its indirectly wholly-owned subsidiary controls the entities by way of controlling the voting rights, governing the financial and operating policies, appointing or removing the majority of the members of their controlling authorities, and casting the majority of votes at meetings of such authorities. In addition, such contractual agreements also transfer the risks and rewards of the entities to the Group’s indirect wholly-owned subsidiary. As a result, the entities are treated as subsidiaries of the Company and their financial statements have been consolidated by the Company.

### 2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended HKFRS Accounting Standard for the first time for the current period’s financial information.

Amendments to HKAS 21

*Lack of Exchangeability*

The nature and the impact of the amended HKFRS Accounting Standard are described below:

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group’s presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

### 3. OPERATING SEGMENT INFORMATION

Six months ended 30 June 2025	Medical services RMB'000 (Unaudited)	Nursing services RMB'000 (Unaudited)	Health management services RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
<b>Segment information (note 4)</b>				
Sales to external customers	69,827	34,624	74,154	178,605
Cost of sales	(60,521)	(28,023)	(50,748)	(139,292)
<b>Segment gross profit</b>	<b>9,306</b>	<b>6,601</b>	<b>23,406</b>	<b>39,313</b>
<u>Reconciliation:</u>				
Selling and distribution expenses				(31,008)
Research and development expenses				(19,570)
Administrative expenses				(43,268)
Reversal of impairment losses on financial and contract assets, net				7,781
Other income				3,293
Other expenses				(866)
Other gains, net				4,921
Finance income				5,715
Finance costs				(11,933)
Share of losses of associates				(4,670)
Loss before tax				(50,292)
Six months ended 30 June 2024	Medical services RMB'000 (Unaudited)	Nursing services RMB'000 (Unaudited)	Health management services RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
<b>Segment information (note 4)</b>				
Sales to external customers	87,615	24,478	67,121	179,214
Cost of sales	(72,079)	(17,955)	(46,624)	(136,658)
<b>Segment gross profit</b>	<b>15,536</b>	<b>6,523</b>	<b>20,497</b>	<b>42,556</b>
<u>Reconciliation:</u>				
Selling and distribution expenses				(37,345)
Research and development expenses				(21,270)
Administrative expenses				(43,727)
Impairment losses on financial and contract assets, net				(3,619)
Other income				12,831
Other gains, net				417
Finance income				8,498
Finance costs				(14,041)
Share of losses of associates				(4,927)
Loss before tax				(60,627)

#### 4. REVENUE AND OTHER INCOME

An analysis of revenue is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Revenue from contracts with customers	<b>178,605</b>	179,214

##### Disaggregated revenue information for revenue from contracts with customers

##### **For the six months ended 30 June 2025**

<u>Segments</u>	<b>Medical services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Nursing services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Health management services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Total</b> <b>RMB'000</b> <b>(Unaudited)</b>
<b>Geographical market</b>				
Mainland China	69,827	34,624	74,154	178,605
<b>Timing of revenue recognition</b>				
Recognised at a point in time	67,210	34,500	74,009	175,719
Recognised over time	2,617	124	145	2,886
<b>Total</b>	<b>69,827</b>	<b>34,624</b>	<b>74,154</b>	<b>178,605</b>

##### **For the six months ended 30 June 2024**

<u>Segments</u>	<b>Medical services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Nursing services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Health management services</b> <b>RMB'000</b> <b>(Unaudited)</b>	<b>Total</b> <b>RMB'000</b> <b>(Unaudited)</b>
<b>Geographical market</b>				
Mainland China	87,493	24,479	67,120	179,092
Other regions	122	—	—	122
<b>Total</b>	<b>87,615</b>	<b>24,479</b>	<b>67,120</b>	<b>179,214</b>
<b>Timing of revenue recognition</b>				
Recognised at a point in time	79,372	24,027	66,752	170,151
Recognised over time	8,243	452	368	9,063
<b>Total</b>	<b>87,615</b>	<b>24,479</b>	<b>67,120</b>	<b>179,214</b>



An analysis of other income is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Government grants*	<b>1,620</b>	7,732
Investment return on wealth management products	<b>1,568</b>	4,872
Value added tax (“VAT”) refund and VAT reduction	–	127
Refund of service fee for withholding individual income tax	<b>105</b>	91
Other items	–	9
	<hr/>	<hr/>
<b>Total</b>	<b>3,293</b>	<b>12,831</b>
	<hr/> <hr/>	<hr/> <hr/>

\* Government grants mainly include one-time incentives for listed companies and project-based subsidies to support regional development, encourage innovation, and promote digital transformation.

## 5. LOSS BEFORE TAX

The Group’s loss before tax is arrived at after charging/(crediting):

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Cost of sales of hardware, software, raw materials and others	<b>108,619</b>	110,765
Depreciation of property, plant and equipment	<b>4,222</b>	4,046
Depreciation of right-of-use assets	<b>10,442</b>	10,824
Amortisation of intangible assets	<b>313</b>	344
Employee benefit expense (including directors’ and chief executive’s remuneration):		
Wages, salaries and bonuses	<b>58,497</b>	66,484
Share-based compensation expenses	<b>11,571</b>	9,182
Social security costs and housing benefits	<b>14,222</b>	15,961
Other employee benefits	<b>2,149</b>	4,136
	<hr/>	<hr/>
<b>Total</b>	<b>86,439</b>	<b>95,763</b>
	<hr/>	<hr/>
Foreign exchange differences, net*	<b>(275)</b>	(527)
(Reversal of impairment of)/impairment of financial and contract assets, net:		
Impairment of/(reversal of impairment of) long-term trade receivables, net	<b>3,346</b>	(1,495)
(Reversal of impairment of)/impairment of trade receivables, net	<b>(11,144)</b>	6,892
Impairment of/(reversal of impairment of) other receivables, net	<b>201</b>	(1,993)
(Reversal of impairment of)/impairment of contract assets, net	<b>(184)</b>	215
	<hr/>	<hr/>
<b>Total</b>	<b>(7,781)</b>	<b>3,619</b>
	<hr/>	<hr/>
Impairment loss on inventories*	<b>357</b>	133
Service fee for purchase of wealth management products**	<b>866</b>	–
Fair value gains on financial assets at fair value through profit or loss, net***	<b>(592)</b>	(1,311)
Gain on partial disposal of equity interest in an associate***	<b>(4,459)</b>	–
Loss on disposal of property, plant and equipment, net***	<b>473</b>	758
(Gain) /loss on partial or full termination of the lease, net***	<b>(103)</b>	92
	<hr/> <hr/>	<hr/> <hr/>

- \* These items are included in “Administrative expenses” in the interim condensed consolidated statement of profit or loss and other comprehensive income.
- \*\* This item is included in “Other expenses” in the interim condensed consolidated statement of profit or loss and other comprehensive income.
- \*\*\* These items are included in “Other gains, net” in the interim condensed consolidated statement of profit or loss and other comprehensive income.

## 6. FINANCE INCOME AND COSTS

An analysis of finance income and costs is as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<b>Finance income</b>		
Interest income	<u>5,715</u>	<u>8,498</u>
<b>Finance costs</b>		
Interest on bank borrowings	(10,506)	(11,945)
Interest on lease liabilities	(1,427)	(2,080)
Interest on long-term payables	<u>–</u>	<u>(16)</u>
	<u><b>(11,933)</b></u>	<u><b>(14,041)</b></u>

## 7. INCOME TAX

No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong during the six months ended 30 June 2025 (for the six months ended 30 June 2024: Nil).

In Mainland China, the companies are subject to the PRC corporate income tax rate of 25% (for the six months ended 30 June 2024: 25%) except for one (for the six months ended 30 June 2024: One) PRC subsidiary which is entitled to a preferential tax rate of 15% because it is accredited as a High and New Technology Enterprise.

The income tax credit of the Group is analysed as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Current – Mainland China		
Charge for the period	1,028	306
Underprovision in prior periods	261	16
Deferred	<u>(1,606)</u>	<u>(465)</u>
Total tax credit	<u><b>(317)</b></u>	<u><b>(143)</b></u>

## 8. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 841,876,805 (2024: 841,876,805) outstanding during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2025 and 2024 in respect of a dilution as the impact of the share options outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculation of loss per share is based on:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<u>Loss</u>		
Loss attributable to ordinary equity holders of the parent, used in the loss per share calculation	<b>(48,886)</b>	<b>(59,559)</b>
	<b>Number of shares</b>	
	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
<u>Shares</u>		
Weighted average number of ordinary shares outstanding during the period used in the loss per share calculation	<b>841,876,805</b>	<b>841,876,805</b>

## 9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired assets at an aggregate cost of RMB1,201,000 (for the six months ended 30 June 2024: RMB4,920,000) and disposed of assets with an aggregate book value of RMB593,000 (for the six months ended 30 June 2024: RMB896,000), resulting in a net loss on disposal of RMB473,000 (for the six months ended 30 June 2024: RMB758,000).

## 10. RIGHT-OF-USE ASSETS

During the six months ended 30 June 2025, the Group acquired assets at an aggregate cost of RMB5,426,000 (for the six months ended 30 June 2024: Nil) and partially or fully terminated assets with an aggregate book value of RMB2,243,000 (for the six months ended 30 June 2024: RMB8,180,000), resulting in a net gain of RMB103,000 (for the six months ended 30 June 2024: Net loss of RMB92,000).

## 11. INVESTMENTS IN ASSOCIATES

	<b>30 June 2025</b>	<b>31 December 2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
At beginning of the period	<b>169,559</b>	186,993
Share of losses of associates	<b>(4,670)</b>	(17,434)
Partial disposal of equity interest in an associate	<b>(79,559)</b>	—
At end of the period	<b>85,330</b>	169,559

On 20 May 2025, Xikang Healthcare Technology Co., Ltd. (“Xikang Technology”), which is a wholly-owned subsidiary of the Group, Neutech Group Limited and Dalian Xikang Yunshe Kang Travel Investment Management Co., Ltd. (“Dalian Yunshe”) entered into an equity transfer agreement. Pursuant to the agreement, Xikang Technology agreed to transfer its 4.23% equity interest in Dalian Yunshe to Neutech Group Limited at a consideration of RMB30,000,000. In addition, Dalian Yunshe and Neutech Group Limited entered into the capital increase agreement pursuant to which they agreed to subscribe for the increased registered capital of Dalian Yunshe. On 18 June 2025, the above-mentioned equity transfer and capital increase arrangement were completed. Accordingly, the Group’s shareholding in Dalian Yunshe was reduced from approximately 11.83% to 7.15%. According to the latest articles of association of Dalian Yunshe, the Group no longer has the right to nominate directors to Dalian Yunshe, and hence the Group has since been unable to exercise significant influence over Dalian Yunshe, which has been reclassified as an equity investment designated at fair value through other comprehensive income since then. Pursuant to the equity transfer agreement, the consideration for the equity transfer is scheduled to be collected in a lump sum on 30 September 2025. The fair value of the remaining equity interest is determined using the recent transaction method and the gain on partial disposal of equity interest in an associate is RMB4,459,000.

## 12. LONG-TERM TRADE RECEIVABLES

	<b>30 June 2025 RMB’000 (Unaudited)</b>	31 December 2024 RMB’000 (Audited)
Long-term trade receivables	<b>14,658</b>	18,169
Less: Impairment	<b>(8,002)</b>	(4,655)
	<b>6,656</b>	13,514
Less: Long-term trade receivables due within one year	<b>(3,342)</b>	(7,654)
Net carrying amount	<b>3,314</b>	5,860

The Group signed contracts with medical institutions, governments and enterprises in relation to the sale of smart healthcare products. According to the payment terms in the contracts, the total consideration for the sale of smart healthcare products will be collected within 13 months to 10 years.

An ageing analysis of the long-term trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	<b>30 June 2025 RMB’000 (Unaudited)</b>	31 December 2024 RMB’000 (Audited)
Within 3 months	–	6,202
4 months to 1 year	<b>4,138</b>	–
1 to 2 years (excluding 1 year)	–	370
2 to 3 years (excluding 2 years)	<b>5,596</b>	5,082
3 to 4 years (excluding 3 years)	<b>4,924</b>	6,515
	<b>14,658</b>	18,169
Less: Impairment	<b>(8,002)</b>	(4,655)
	<b>6,656</b>	13,514
Less: Long-term trade receivables due within one year	<b>(3,342)</b>	(7,654)
Net carrying amount	<b>3,314</b>	5,860

### 13. TRADE RECEIVABLES

	<b>30 June 2025 RMB'000 (Unaudited)</b>	31 December 2024 RMB'000 (Audited)
Trade receivables	<b>205,663</b>	230,982
Less: Impairment	<b>(117,864)</b>	(129,008)
Net carrying amount	<b>87,799</b>	101,974

The credit terms given to trade customers are determined on an individual basis. The normal credit period of trade receivables related to comprehensive health management services (included in health management services) is mainly within 90 days, while the normal credit period of trade receivables related to medical services, nursing services and health management services (excluding comprehensive health management services) is mainly within one year. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

Included in the Group's trade receivables as at 30 June 2025 are amounts due from the Group's related parties of RMB5,429,000 (31 December 2024: RMB6,004,000), which are repayable on credit terms similar to those offered to the major customers of the Group.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	<b>30 June 2025 RMB'000 (Unaudited)</b>	31 December 2024 RMB'000 (Audited)
Within 3 months	<b>30,126</b>	58,592
4 months to 1 year	<b>47,189</b>	29,035
1 to 2 years (excluding 1 year)	<b>27,861</b>	40,945
2 to 3 years (excluding 2 years)	<b>34,841</b>	45,768
3 to 4 years (excluding 3 years)	<b>24,215</b>	15,666
4 to 5 years (excluding 4 years)	<b>7,034</b>	5,162
Over 5 years	<b>34,397</b>	35,814
	<b>205,663</b>	230,982
Less: Impairment	<b>(117,864)</b>	(129,008)
Total	<b>87,799</b>	101,974

The movements in the loss allowance for impairment of trade receivables are as follows:

	<b>For the six months ended 30 June</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
At beginning of period	<b>129,008</b>	94,429
Impairment losses (reversed)/recognised	<b>(11,144)</b>	6,892
Amount written off as uncollectible	<b>—</b>	(526)
At end of period	<b>117,864</b>	100,795

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e., by customer type). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity.

#### 14. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	<b>30 June</b>	<b>31 December</b>
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
Within 3 months	<b>56,054</b>	99,535
4 to 6 months	<b>14,929</b>	11,185
7 months to 1 year	<b>28,630</b>	16,987
1 to 2 years (excluding 1 year)	<b>19,622</b>	34,656
2 to 3 years (excluding 2 years)	<b>30,166</b>	26,528
3 to 4 years (excluding 3 years)	<b>8,451</b>	10,823
4 to 5 years (excluding 4 years)	<b>3,526</b>	916
Over 5 years	<b>1,343</b>	507
Total	<b>162,721</b>	201,137

#### 15. DIVIDENDS

The board of directors of the Company (the “Board”) has resolved that no interim dividend be declared for the six months ended 30 June 2025 (for the six months ended 30 June 2024: Nil).



## **PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT**

This interim results announcement is published on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the website of the Company at <https://www.xikang.com/>. The interim report of the Company for the six months ended June 30, 2025 will be published on the aforesaid websites of the Stock Exchange and the Company in due course.

By Order of the Board  
**Xikang Cloud Hospital Holdings Inc.**  
**Dr. LIU Jiren**  
*Chairman and Non-executive Director*

Hong Kong, August 27, 2025

*As at the date of this announcement, the Board of the Company comprises Ms. ZONG Wenhong as an executive Director; Dr. LIU Jiren, Mr. XU Hongli, Dr. WANG Nan and Mr. PU Chengchuan as non-executive Directors; and Dr. CHEN Yan, Dr. QI Guoxian and Dr. YIN Guisheng as independent non-executive Directors.*